M-A | SGLT2 inhibitors reduce the risk of kidney disease progression and AKI, irrespective of diabetes status.

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials – The Lancet

Commentaries:

Meta-analysis backs SGLT2 inhibitors for kidney disease – medwire News

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD – TCTMD

Related: RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.

Commentary on Twitter

Our SGLT2 Trialists Consortium meta-analysis *the largest ever* in @TheLancet https://t.co/YlWkRQTDAW

Definitive evidence that SGLT2i ⬇️:
– Kidney failure
– AKI
– CV death
– All-cause death

Regardless of diabetes

Led by @NatalieStaplin @RichardHaynes3 @willkidney #AHA22 pic.twitter.com/uAX15mD9XY

— Brendon Neuen (@brendonneuen) November 6, 2022

Under a Creative Commons Attribution (CC BY 4.0) License